Arcadia CEO Stanley Jacot resigns; CFO Schaefer promoted to CEO, Kawakami named CFO

Arcadia Biosciences, Inc.

Stanley Jacot, Jr. resigned as president, CEO, and director on July 2, 2024; cash severance $288,077 + 12-month option acceleration + COBRA through Feb 2025.
CFO Thomas J. Schaefer appointed president and CEO effective July 5, 2024; he had been CFO since Jan 2023.
Mark Kawakami appointed CFO effective July 5, 2024; he was VP Finance since Jan 2023; base salary $212,063.
Separation Agreement includes general release of claims, confidentiality, and non-disparagement by Jacot.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stanley Jacot, Jr.

president, chief executive officer and director

RKDA · Arcadia Biosciences, Inc.

Effective: 2024-07-02
Successor: Thomas J. Schaefer
Filed: July 8, 2024, 7:59 PM ET

Mr. Jacot resigned as Arcadia’s president, chief executive officer and director.

Appointed

Mark Kawakami

chief financial officer

RKDA · Arcadia Biosciences, Inc.

Effective: 2024-07-05
Filed: July 8, 2024, 7:59 PM ET

Arcadia’s board of directors appointed Mark Kawakami as Arcadia’s new chief financial officer to succeed Mr. Schaefer, effective as of July 5, 2024.

Role change

Thomas J. Schaefer

president and chief executive officer

RKDA · Arcadia Biosciences, Inc.

Effective: 2024-07-05
Successor: Mark Kawakami
Filed: July 8, 2024, 7:59 PM ET

Arcadia’s board of directors appointed Thomas J. Schaefer, Arcadia’s current chief financial officer, to the position of president and chief executive officer of Arcadia, effective as of July 5, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Stanley Jacot, Jr. resigned as president, chief executive officer and director at Arcadia Biosciences, Inc..

Action: resigned
Role: president, chief executive officer and director

Exact text from the filing

Mr. Jacot resigned as Arcadia’s president, chief executive officer and director.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Mark Kawakami was appointed as chief financial officer at Arcadia Biosciences, Inc..

Action: appointed
Role: chief financial officer

Exact text from the filing

Arcadia’s board of directors appointed Mark Kawakami as Arcadia’s new chief financial officer to succeed Mr. Schaefer, effective as of July 5, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas J. Schaefer was appointed as president and chief executive officer at Arcadia Biosciences, Inc..

Action: appointed
Role: president and chief executive officer

Exact text from the filing

Arcadia’s board of directors appointed Thomas J. Schaefer, Arcadia’s current chief financial officer, to the position of president and chief executive officer of Arcadia, effective as of July 5, 2024.

View on SEC.gov

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-082092

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.